SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2067 participants.

Also called NCT03982381

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,067 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03982381
  • EudraCT 2019-001046-17
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03982381. Randomized; single masking; primary purpose treatment. Start 2019-09-05 (actual); primary completion 2026-01-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
Acronym
SMARTEST
Intervention (Drug)
Metformin
Intervention (Drug)
Dapagliflozin 10 MG
Lead sponsor
Uppsala University (class: other)
Collaborator
Uppsala University Hospital (class: other)
Collaborator
Swedish Healthcare Regions (class: not stated)
Collaborator
National Board of Health and Welfare, Sweden (class: other government)
Collaborator
The Swedish National Diabetes Register (class: not stated)

Record details

Record id
cardio:ct-nct03982381
Content hash
082c05de619f82b1b5e3e274c0d7d4d3092eb3d5789a5ba74f2456e4cd857830